Bullish indicating open at $55-$60, IPO prices at $37
Emily Pimblett, the Senior Vice President of Finance and Chief Accounting Officer at Climb Bio, Inc. (NASDAQ:CLYM), recently reported a sale of company stock. According to a Form 4 filing, Pimblett sold 1,199 shares of Climb Bio’s common stock on March 20, 2025, at a weighted average price of $1.31 per share, totaling approximately $1,570. This transaction was part of a 10b5-1 trading plan adopted in April 2024 to cover tax withholding obligations related to the vesting of restricted stock units (RSUs). The sale comes as CLYM trades near its 52-week low of $1.20, having declined 84% over the past six months. InvestingPro analysis suggests the stock is currently undervalued.
In addition to the sale, Pimblett also executed a transaction involving 5,000 restricted stock units that converted into common stock on March 18, 2025. This transaction did not involve any cash exchange, as each RSU was converted into one share of common stock. Following these transactions, Pimblett now holds 15,130 shares of Climb Bio directly, representing a small portion of the company’s $90.75 million market capitalization. For more detailed insider trading analysis and additional insights, visit InvestingPro, which offers 7 more key tips about CLYM’s financial health and market position.
In other recent news, Climb Bio, Inc. has appointed Perrin Wilson, Ph.D., as its new Chief Business Officer. With over 17 years of experience in the pharmaceutical and biotech sectors, Dr. Wilson is expected to lead pre-commercial planning, communications, and business development for the company. Prior to joining Climb Bio, she held significant roles, including Senior Vice President at Nuvalent, and contributed to major acquisitions at Forma Therapeutics/Novo Nordisk and Takeda. Her experience includes leading transactions such as a $1.1 billion and a $5.2 billion acquisition of ARIAD. Climb Bio’s President and CEO, Aoife Brennan, expressed confidence in Dr. Wilson’s abilities to drive growth and advance the company’s leadership in immune-mediated disease treatments. Dr. Wilson also noted Climb Bio’s strong financial position and its promising pipeline, which includes budoprutug and CLYM116, both targeting immune-mediated diseases. These developments reflect the company’s ongoing efforts to enhance its strategic and commercial capabilities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.